^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

529P - Ramucirumab plus docetaxel after combination chemoimmunotherapy in patients with non-small cell lung cancer: A prospective observational study

Published date:
11/27/2023
Excerpt:
This multicenter prospective study aimed to investigate the efficacy and safety of RAM plus DOC after combined chemoimmunotherapy….The ORR and DCR were 36.4% (95% CI: 22.4–52.2) and 72.7% (95% CI: 57.2–85.0). High VEGF-D groups had significantly shortened PFS and OS. The combination of high VEGF-A and low VEGF-D had a longer PFS than other groups.
Secondary therapy:
docetaxel